

REvoLd: Ultra-Large Library Screening with an Evolutionary Algorithm in Rosetta

Paul Eisenhuth^{1,2*}, Fabian Liessmann¹, Rocco Moretti³,
Jens Meiler¹⁻⁴

¹Institute for Drug Discovery, Leipzig University, Leipzig, 04103, Germany.

²Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Leipzig University, Leipzig, 04105, Germany.

³Center for Structural Biology, Vanderbilt University, Nashville, 37235, TN, USA.

⁴Department of Chemistry, Vanderbilt University, Nashville, 37235, TN, USA.

*Corresponding author(s). E-mail(s): eisenhuth@cs.uni-leipzig.de;

Abstract

Ultra-large make-on-demand compound libraries now contain billions of readily available compounds. This represents a golden opportunity for *in-silico* drug discovery. One challenge, however, is the time and computational cost of an exhaustive screen of such large libraries when receptor flexibility is taken into account. We propose an evolutionary algorithm to search combinatorial make-on-demand chemical space efficiently without enumerating all molecules. We exploit the feature of make-on-demand compound libraries, namely that they are constructed from lists of substrates and chemical reactions. Our novel algorithm RosettaEvolutionaryLigand (REvoLd) explores the vast search space of combinatorial libraries for protein-ligand docking with full ligand and receptor flexibility through RosettaLigand. A benchmark of REvoLd on five drug targets showed improvements in hit rates by factors between 869 and 1,622 compared to random selections. REvoLd is available as an application within the Rosetta software suite.

Scientific contribution statement: This work formulates an evolutionary algorithm for optimization and exploration of ultra-large make-on-demand

libraries. We demonstrate that our approach results in strong and stable enrichment, offering the most efficient algorithm for drug discovery in ultra-large chemical space to date.

Keywords: Computer-aided drug discovery, evolutionary algorithm, ultra-large chemical space, make-on-demand library, small molecules, screening

1 Introduction

Drug discovery is a complex and time-consuming process. A campaign typically starts with target selection, followed by hit identification. Hit identification is usually done through screening experiments. While other factors play a role, chances of success increase with the number of tested compounds. However, acquiring a large number of molecules is expensive and testing them in bulk requires specialized infrastructure [52]. One widely adopted solution is virtual high throughput screening (vHTS), where molecules are pre-screened on computers and filtered for predicted activity [46]. One of the most significant challenges limiting vHTS is the size of the chemical space, which is estimated to contain up to 10^{60} possible drug-like molecules [5]. In addition to the lack of computational capacity to store and screen such a large number of molecules, defining a chemical space that is drug/lead-like and synthetically accessible presents a hindrance [9, 15, 26]. A wide range of technologies have been developed to generate molecules tailored to specific areas of interest. However, many computational approaches are never thoroughly tested as the barrier for synthesis is too high and, thus, compounds are unavailable for *in-vitro* testing [9, 16, 23, 31, 42, 53]. Make-on-demand combinatorial libraries can overcome this challenge if vHTS algorithms can be tailored to sample this focused but still prodigious chemical space. These libraries combine simple building blocks through robust reactions to form billions of readily and economically available molecules. In the best-case scenario, they allow the confirmation of bioactive hit molecules from *in-silico* prediction through *in-vitro* evaluation within a few weeks [22, 34, 54]. However, the increased make-on-demand chemical space is not only an opportunity but also a challenge. A small number of vHTS campaigns have been conducted on molecule libraries exceeding a hundred million compounds, even fewer exceeding billions, and they all required substantial computational resources [1, 21, 34, 35]. Additionally, most of the computational time in such campaigns is spent on molecules of no further interest for the following steps of the drug discovery campaign due to low hit rates.

To date, several solutions have been proposed to address this problem. The Deep Docking platform [18, 19] utilizes a mixture of conventional docking algorithms and neural networks to screen a subset of the target space and quantitative structure-activity relationship (QSAR) models to evaluate the remaining target space. However, this approach still requires the docking of tens to hundreds of millions of molecules and calculating QSAR descriptors for the whole billion-sized molecular library. A similar idea is used by Luttens *et al.* [33].

Another promising solution is V-SYNTHES [44, 45]. Instead of docking the final molecules, V-SYNTHES starts with docking of single fragments, picking the most promising ones and iteratively adding more fragments to the growing scaffolds until final molecules are built. Chemical Space Docking is essentially the same approach as V-SYNTHES, but is a general instruction instead of being a ready-to-use software [4]. A similar approach, called Targeted Exploration [40], filters the synthons of Enamine’s REAL space [14] for similarity to known binders. The most promising synthons are used to enumerate ligand libraries. Search on chemical space near functional molecules requires previous structural knowledge of the molecules, which is not always available. To create such space, millions of computational docking procedures have to be performed.

Recently, [37] published an evolutionary algorithm called Galileo, to optimize molecules in chemical combinatorial space. The algorithm is not tailored towards a specific optimization goal or chemical space but accepts any function which assigns a score to a molecule and treats reaction rules as general as possible. The algorithm was tested for a similarity search and optimization of pharmacophores, although with mixed success. A total of five million fitness calculations in the context of structure-based drug design makes expansive docking models unfeasible. However, the algorithm showed promising performance. This is in line with recent analysis on the potentials of genetic algorithms, showing that their capabilities are on par with modern deep learning methods [17, 51]. Evolutionary algorithms have been used for decades in computer-aided drug discovery (CADD) and were implemented by multiple research groups [8, 25, 31, 47, 48]. They were all highly successful in finding and optimizing promising compounds but shared one common drawback - synthetic accessibility. One recently published evolutionary algorithm even puts most of its research effort into assuring easy synthesizability [28].

Building on these findings, we propose RosettaEvolutionaryLigands or short REvoLd: An evolutionary algorithm optimizing entire molecules from the Enamine REAL space [14]. It reveals promising compounds with just a few thousand docking calculations, continues to discover new scaffolds if run multiple times, and enforces high synthetic accessibility. Furthermore, REvoLd’s enrichment capabilities seem to be independent of the size of the space searched.

2 Implementation

Evolutionary algorithms mimic Darwinian evolution [13]. Starting from a random population, individuals are altered, and selective pressure is applied through a fitness function. In each iteration, individuals that are discarded due to their fitness will be replaced by new individuals created through reproduction. In CADD, evolutionary algorithms often utilize docking scores as fitness functions to minimize the free energy between the protein target and the ligand. Reproduction typically consists of mutation and crossover, where mutation alters small parts of the current molecule, like removing or adding a single atom or functional group. Crossover, on the other hand, recombines two or more promising solutions, for example by cutting two molecules in half and recombining their fragments [30]. Our proposed algorithm sticks to this paradigm

[25]. REvoLd allows for all parameters to be changed and adapted by the user. Several selection and reproduction methods can be freely combined to form customized evolutionary protocols.

2.1 Combinatorial Libraries

While our reproduction functions follow the core ideas of evolutionary algorithms, their main novelty is their strict limitation to the chemical space defined by the make-on-demand library. Examples of such libraries are Enamine REAL space, Otava CHEMriya space, and WuXi LabNetwork GalaXi space [14, 41, 55]. While they all differ in size and include different molecules, they all define chemical reactions and sets of fragments that can be combined through these reactions. This causes an exponentially larger chemical space of billions of molecules defined through a few hundred reactions and hundreds of thousands or at most single-digit million fragments [3, 22]. These definitions are exploited by our reproduction functions. Each individual in our algorithm represents a single molecule. It is defined through a reaction and a list of fragments used for that specific reaction (figure 1).




Fig. 1 Example of fragment combinations. **A** Fragments are defined with attachment points or reaction handles. These are used as hinges to freely combine multiple fragments from predefined lists. For example, the yellow pentagon can be combined with all three fragments in list 2 to form three different products. The product space grows exponentially as both fragment lists grow linearly. **B** An example of mutation and crossover. The mutation aims to replace the fragment from list 1. A local similarity search through all those fragments yielded the blue hexagon. Next, a crossover between the new molecule and another one happens. Both parents contribute one fragment each and create again a new molecule which resembles both its predecessors.

2.2 Algorithm overview

Following typical evolutionary algorithms, REvoLd starts with a random population. An overview of the optimization process is given in figure 2. Initial molecules, called individuals, are generated through picking a random reaction and picking one random suitable synthon for each of the reaction's positions. The reaction is picked by

a weighted random selection. The weight is the number of possible distinct educts of each reaction. Next, each of these random molecules is docked against the target protein following the RosettaLigand protocol resulting in 150 complexes per molecule [12, 36]. Each of these complexes is used to calculate interface energies between ligand and protein. The lowest calculated interface energy is used as fitness score. The first population is formed through appliance of selective pressure through a freely chosen main selector in order to reduce the number of individuals down to the selected maximum size.




Fig. 2 General overview of REvoLd’s optimization cycle. Starting from a random population, fitness scores are calculated through ligand docking and solutions are discarded through selective pressure. Alterations to molecules are introduced through offspring factories iteratively. The cycle is continued until a set number of generations is reached.

An evolutionary optimization cycle follows to successively select fit individuals, e.g., molecules, for reproduction. Every cycle consists of a sequence of reproduction steps. Each step selects individuals from the previous generation for a given reproduction pattern. The selected individuals remain in the pool for further reproduction steps per default but can be removed if desired. Next, new molecules are docked to calculate their fitness and the main selector is applied to reduce the new population down to the selected maximum. A cycle is finished by checking if the maximum number of generations is reached. If not, another cycle follows, otherwise the algorithm ends and reports all analyzed molecules.

2.3 Selectors

In the current version of REvoLd, three different selectors were implemented, all of which can be utilized as the main selector and for selecting individuals for reproduction. The simplest selector, called ElitistSelector, simply selects the fittest individuals. The other two selectors, TournamentSelector and RouletteSelector, are non-deterministic and may allow worse scoring individuals to be selected for reproduction and to advance generations, in order to explore chemical space further and potentially escape local minima [20]. The RouletteSelector takes the relative differences of fitness scores into account by assigning selection chances based on them. If an individual has a fitness two times better than another individual the first will have a two times higher chance of selection. TournamentSelector on the other hand solely considers the ranking of individuals. A set number of individuals is selected randomly to participate in a tournament. This number is referred to as tournament size. All individuals are sorted by their fitness and are granted a chance to accept their selection. Therefore, a larger tournament size means a smaller chance to be selected for less fit individuals. In addition, all selectors have the option to either remove selected individuals from the pool, or to keep them in the pool to potentially participate in more reproduction steps.

2.4 Reproduction

Reproduction is implemented through three different offspring factories. Each factory needs to be linked to one selector which provides it with a set of selected individuals. Each factory uses these individuals to produce a set number of offspring individuals. This is applied sequentially following a user specified evolutionary protocol. The IdentityFactory simply copies the input individuals unchanged into the offspring generation. This is done to preserve and keep already found solutions and allow them to proceed through multiple generations.

The MutatorFactory applies point mutation to all its input individuals. A point mutation is either the change of one fragment to another fitting fragment or a change of reaction. This is expected to introduce small local perturbations to guide individuals into local energy minima. Switching fragments is easy since each reaction provides a list of suitable synthons for all positions and those can be freely replaced by each other. RDKit’s implementation of extended connectivity fingerprints and Tanimoto similarity are used to control the impact of synthon mutation [2, 29, 43]. Fingerprints are calculated for all fragments during database loading at program initialization. When a new fragment needs to be selected, all suitable replacements are collected into one list and their similarity to the origin fragment is calculated. Next, cutoff values are applied to ensure a minimal and maximum similarity. The final new fragment is then selected using a weighted random sample with similarity as weights. This can be used to enforce drastic mutations or to allow only fine-grained changes. The mutation of reactions is more challenging. First, a new reaction is selected. Second, new fragments for each position are selected based on maximal Tanimoto similarity to previously used fragments, to limit the changes induced on the molecule.

The last possibility to create offspring is the CrossoverFactory. It randomly combines all its input individuals into parental pairs which are used to create offspring inheriting traits from them. One parent provides the reaction used for the offspring, and each parent provides a random number of fragments, but always at least one. If both parents use the same reaction, their fragments can be freely combined. If they use different reactions, a local similarity search is used to find the most similar fragments in the reaction used by the offspring, as it is done in the MutatorFactory.

2.5 Score calculation

Each individual represents a molecule which is a potential hit candidate. To estimate its fitness, or score, we use the ligand docking protocol RosettaLigand and its recommended preprocessing steps [12, 36]. First, RDKit [29] is used to turn the SMARTS and SMILES representations of the individual’s reaction and fragments, respectively, into RDKit reactions and molecules and to run the reaction with the selected fragments. RDKit is further used to calculate a three-dimensional embedding of the molecule and a list of low-energy conformers. These are passed to the RosettaLigand docking protocol to calculate the protein-ligand complex following a Monte Carlo optimization. Briefly, the RosettaLigand protocol consists of an initial placement of the ligand in a user-defined position, which is ideally a previously identified or known binding site. Next, a coarse-grained docking step successively applies rotation, translation, and conformer sampling to guide the ligand into close contact with the protein. This is followed by a high-resolution docking step, which applies only small changes to the ligand and optimizes protein sidechains. Lastly, a final minimization step optimizes the current solution into a local minimum. This protocol is repeated 150 times, and the lowest (best) reported protein-ligand interface energy is used as the basis of the efficiency score.

2.6 Final Protocol

There are a total of seven different reproductions in our final protocol, but protocols can be freely adapted. This protocol was developed through optimizing hit rates, which is explained in section 3.2. The first two steps are intended to cause small refinements on promising molecules from the previous generation. The next two steps potentially use the same molecules but make sure more impactful changes are applied to enhance exploration of chemical space, where step 3 increases exploration within the same reaction and step 4 ensures different reactions are explored as well. Step 5 moves the best molecules unchanged to the next generation and removes them from the pool of reproduction candidates. This is done to preserve the best solutions for future generations and to allow optimization of less optimal molecules through the final two steps.

1. **Moderate mutations:** A roulette wheel selector selects 15 individuals and a total of 30 new molecules are produced through mutation, with every parent being used twice. Mutations occur twice as often on fragments instead of reactions. Fragment selection is biased towards high similarity with an enforced minimal Tanimoto similarity of 0.6. Selected parents remain unchanged in the current pool.

2. **Excessive crossover:** A roulette wheel selector selects 15 individuals and a total of 60 new molecules are produced through crossover. Parents are randomly paired to generate one new molecule. This is repeated until enough offspring are generated. Selected parents remain unchanged in the current pool.
3. **Drastic mutations:** Like step 1, but only fragments can be mutated, not reactions. Furthermore, fragment selection is still biased towards higher similarity, but a maximum similarity of 0.25 is used as hard cutoff.
4. **Reaction mutation:** Like step 1, but only reactions are mutated to guarantee exploration of chemical spaces defined by different reactions.
5. **Identity:** The 15 best molecules from the current pool are passed unchanged to the next generation. They are removed from the current pool afterwards.
6. **Moderate mutations:** Same as step 1, but since the 15 best molecules were removed in step five, individuals with a worse fitness have a higher chance to be selected.
7. **Excessive crossover:** Same as step 2, but again with a higher chance for worse molecules.

These steps strike a good balance between exploration and exploitation of chemical space. This cycle is repeated until 30 generations are done, and all molecules from all generations are reported. REvoLd saves the best-scoring protein-ligand complexes calculated during docking for each individual. Our final protocol uses a tournament selector as main selector with tournament size 15 and acceptance chance of 0.75. The initial population size is 200, the maximum number of individuals to pass between generations is 50.

3 Results

3.1 Ligand Efficiency

Since many of RosettaLigand’s energy terms depend on the size of the molecule, we observed the well-known bias towards larger ligands in our first REvoLd runs. Molecules were getting larger and larger with every generation, since larger molecules can form more interactions with the target protein and therefore receive better scores. However, this does not accurately reflect experimental findings [24]. To address this issue, we normalized the interface energy and tested four different methods with $n \in \{1, 2, 3, 4\}$:

$$fitness_n(x) = \frac{energy(x)}{\sqrt[n]{heavyatoms(x)}} \quad (1)$$

where $energy(x)$ is the interface energy between the protein target and ligand x calculated by RosettaLigand and $heavyatoms(x)$ is the number of non-hydrogen atoms in the ligand x . Increasing n essentially decreases the penalty for large molecules. We found $n = 2$ to perform best. Detailed results can be found in Appendix A. This measure is the geometric mean between the predicted binding energy and the ligand efficiency. It strikes a good balance between biasing against too large and too small molecules. We call this score “ligand interface delta square root normalized” or short

lid_root2. It will be used throughout the rest of the paper whenever we report fitness or docking scores.

3.2 Hyperparameter and protocol optimization

REvoLd is very flexible and has endless potential protocols (e.g., combinations of selectors, reproduction steps, and several global parameters). To allow for quick testing and optimization of the evolutionary protocol, we created a subset of the Enamine REAL Space consisting of one million molecules. Our test set was produced through four two-component reactions and 500 fragments per reagent positions. The reactions and fragments were selected to minimize similarity between all fragments used in order to create a rigid similarity landscape, which is usually harder to navigate and optimize within, and to provide a high diversity of possible molecules. All one million molecules were docked with RosettaLigand against the human dopamine D3 receptor (PDB ID: 3PBL, [7]) to have their scores readily available, and to allow us to assess how close the algorithm gets to the global minimal score. We set the best scoring 1,000 molecules (0.1%) from this set as virtual hits. The selection of a rigid similarity landscape as well as optimizing only for a single target is potentially suboptimal for protocol optimization, but we did not observe a deterioration of hit rates when switching to the later explained more realistic benchmark.

An iterative approach was used to test different combinations of selection and reproduction mechanics and run parameters. Initially, we selected parameters to bias towards the fittest individuals, allowing only them to mutate and reproduce. This setting proved to converge very fast towards hit molecules. Its downside was limited exploration of the target space. We introduced several changes to our protocol to offset that effect. First, we increased the number of crossovers between fit molecules to enforce more variance and recombination between well-suited ligands. Second, we added an additional mutation step which switches single fragments to low similarity alternatives. This keeps well-performing parts of promising molecules intact but enforces huge changes on small parts of it. And third, another mutation step which only changes the reaction of a molecule and searches for similar fragments within the new reaction group. This opens larger parts of the combinatorial space for screening. These changes increased the number and diversity of virtual hits tremendously. As a last change, we introduced a second round of crossover and mutation excluding the fittest molecules, thus allowing worse scoring ligands to improve and carry their molecular information forward. These changes reliably improved hit rates. Details on tested parameter combinations as well as their hit rates can be found in Appendix B.

Regarding the size of the random start population, we found that 200 initially created ligands offer enough variety to start the optimization process. More initial ligands might increase the chance to discover good binders immediately, but greatly increases run time costs. Fewer initial molecules on the other hand have less chance to capture promising structural elements. Next, we tested how many individuals should be allowed to advance to the next generation and found 50 to perform best. Larger populations carry more noise through the generations which decreases the effectiveness of all reproduction steps, but smaller populations are too homogeneous and therefore hinder exploration of chemical space. Lastly, we found 30 generations of optimization

to strike a good balance between convergence and exploration. Good solutions are usually unveiled after 15 generations, but only after 30 generations a flattening of discovery rates has been observed. The algorithm never fully converges and continues to discover good new molecules even after 400 generations, but the hit rates become smaller and smaller. Therefore, we advise multiple independent runs instead. The random starting population seeds different paths which yield different high scoring motifs. Since each run unveils new promising molecules, the exact number of required runs is solely depending on desired amount of hits.




Fig. 3 Examples of score development during single REvoLd runs against each selected target. Solid lines show the best score found up to a certain generation. The dashed line shows the 10th best score, the dotted the 100th best score and dashed-dotted the median. The runs which reported the best scoring molecule for each target were selected as examples here. All scores within the grey area are better than the best scoring known active.

Additionally, we observed that our algorithm was unable to discover the lowest scoring molecule of the benchmark test subset of one million molecules. This might be related to the mentioned intended ruggedness of our scoring landscape which traps runs at local minima. On the other side, it is not uncommon to observe only close-to-optimal solutions from meta-heuristic optimization algorithms like evolutionary algorithms. Considering REvoLd’s purpose we postulate that this is not a flaw, since structure-based CADD campaigns almost never want to discover the single best scoring compound, but many promising compounds which will enrich hit rates in *in-vitro* experiments.

3.3 Benchmark under realistic conditions

Based on the first results and selected parameters, we moved on to more realistic benchmarking conditions, utilizing our largest available Enamine REAL space [14] with over 20 billion molecules at that time. The reaction SMARTS and reagent SMILES were obtained directly from Enamine under a non-disclosure agreement in January 2022. We assembled a benchmark-set of five proteins as drug targets. All are well-researched with high throughput screening (HTS) data available and high-quality crystal structures deposited in the protein databank (PDB), namely the G protein-coupled receptor (GPCR) orexin receptor type 1 OX1 (PDB: 4ZJC, [57]), the GPCR muscarinic acetylcholine receptor M1 (PDB: 5CXV [50]), the DNA repair enzyme tyrosyl DNA-phosphodiesterase 1 TDP1 (PDB: 6MYZ, [32]), the GPCR neuropeptide Y Y1 receptor (PDB: 5ZBQ, [56]), and last, the tyrosine-protein kinase ABL1 (PDB: 2HZI, [11]). The corresponding HTS data is taken from curated lists of actives from PubChem [6], with the exception of the ABL1 kinase. Its screening data was provided through the directory of useful decoys enhanced (DUD-E), which curated ChEMBL entries [11, 38]. Between 188 and 801 molecules are utilized as known actives. All structures were prepared following the presteps of the RosettaLigand protocol with target sites derived from co-crystallized ligands resolved in complex with the protein structures. All known binders from the used HTS data were docked, again following the RosettaLigand protocol, to use their docking scores to ensure that *lid_root2* helps to enrich molecule sets. Additionally, we sampled 100,000 random molecules from the Enamine REAL space and docked them against each target to compare REvoLd sampling efficiency. We found that the known actives score distribution is more negative than the random sample, indicating that *lid_root2* indeed enriches sets of molecules. Details can be found in Appendix C.

Twenty runs of REvoLd were conducted against each target, docking between 49,000 and 76,000 unique molecules in total per target. The difference in sampled molecules per target is due to the stochastic nature of evolutionary optimization, as one run might produce more duplicates than another. This includes all docked molecules during the evolutionary optimization, not just the last generation. Figure 3 shows the development of scores in a selected run for each target. All runs successfully reported molecules with hit-like scores. Due to the size of the defined chemical space searched and the stochastic nature of our protocol, there was only a small overlap between the runs. We found that between 1.5% and 3% of tested compounds have a Tanimoto

similarity of 1.0 to another compound tested against the same target. These duplicates were removed for further analysis.




Fig. 4 We tested REvoLd against five different protein targets, namely Tyrosyl (**A**), Orexin 1 (**B**), Muscarinic M1 (**C**), Y1 Receptor (**D**) and ABL1 (**E**). We combined the results of 20 independent REvoLd runs against each target into single hit lists and removed duplicates with a Tanimoto similarity of 1.0. A molecule is to be considered a hit if its score is below a given hit limit. The total number of hits from REvoLd for various hit limits is shown together with the number of hits from a random sample on a logarithmic scale. REvoLd tested in total between 49,000 and 76,000 molecules, the random samples always consisted of 100,000 molecules. Therefore, we additionally plot the normalized enrichment of REvoLd over the random sample for various hit limits.

To assess the overall sampling performance we use enrichment factors. As it is often the case for *in-silico* evaluations, we assume a perfect predictive power for a scoring function at a given threshold and that all compounds scoring better than this threshold will be active in experimental validation. This decouples the performance of

a sampling algorithm from its underlying scoring method. The number of hits achieved through a selected sampling method is compared to the number of hits from a random sample. For better comparability, we followed the enrichment factor proposed with V-SYTNHES [44] but added a normalization factor for sample sizes. This is implicitly still the same function as V-SYNTHES as they used samples of same size:

$$EF_i(x) = \frac{HitRate_i(x)}{HitRate_{rs}(x)} \quad (2)$$

where EF_i is the enrichment factor of method i , x defines the score limit, rs is the random sample and

$$HitRate_i(x) = \frac{|\{m \mid m \in M_i, score(m) < x\}|}{|M_i|} \quad (3)$$

where M_i is the set of all molecules sampled with method i . The enrichment rate can be interpreted as how many more hits can be expected from a constant sample size or how much less molecules need to be sampled for the same amount of hits. We propose to use this calculation for all following exploration algorithms for better comparability.

Figure 4 reports absolute hit numbers of REvoLd and the random sample for different hit limits as well as the normalized enrichment of REvoLd over the random sample. REvoLd achieves maximum enrichments up to 869 and 1,622 between all five targets, outperforming all currently available algorithms which enable drug discovery in ultra-large libraries. Additionally, figure 4 shows, that REvoLd is able to report hundreds of hits for much stricter hit limits than a random sampler. We also want to report the enrichment rates using the score of the best scoring known active as hit limit following widespread practice. REvoLd achieves enrichments in four cases between 200 and 532. No such enrichment can be reported for the ABL1 kinase, since the random sample did not include a single molecule scoring better than the best scoring known active, but REvoLd unveiled 99 such compounds. Using the best scoring known active as hit limit can be important because scoring functions tend to overrate molecules showing certain artificially favored structural features. At the same time, this limit alone falls short to compare sampling strategies capabilities to optimize into local minima.

3.4 Qualitative analysis of reproduction mechanics

We conducted a qualitative investigation of the effects of mutation and crossover on a few examples using REvoLd’s reproduction functionalities. We found that the *in-silico* functionalities effectively mimic the alterations to molecules typically conducted by medicinal chemists. Mutation enabled the introduction of small local changes, such as increased flexibility of certain parts of the molecules or alteration of its geometry through changing the attachment atom of a ring. Crossover, on the other hand, recombined promising motifs into new molecules, effectively transferring and combining knowledge from two separate ligands. This resemblance of medicinal chemistry

was never intentionally developed or encoded but emerges naturally from evolutionary optimization paradigms. Figure 5 illustrates both operations for one example, including the change of fitness scores. The observed worsening of scores between C to D and G to H respectively also highlights the importance of selective pressure to allow temporally worse scores for new molecules. Both shown mutation steps introduce disadvantageous changes, but the resulting molecules recombine into the best-found solution.




Fig. 5 Example of the family tree for the best scoring molecule for ABL1 showcasing mutation and crossover. **A** and **B** recombined through crossover into **C**, which mutated to **D**. Here, **A** includes a tetrazole ring, a common motif in many FDA approved drugs. Both **A** and **B** are containing a 1,2,4-triazole, representing the basis-structure to combine it to **C**. From **C** to **D** a mutation changes the position of the oxymethylpyridine at the benzyl-group from 4 to 3. Again, in **E** a compound containing a tetrazole and a 1,2,4-triazole is recombined through crossover, but this time while adding a 3-methyl,4-bromo-benzyl group from **F** to the offspring **G**. A mutation derivatizes the [1,2,4]triazolo[1,5-a]pyridine from **G** to **H**'s oxybenzyl-moiety. Finally, both **D** and **H** recombine into **I**, introducing the tetrazole-triazole-system from both **H** and **D** while including the pyrazole from **D** and the 3-methyl,4-bromo-benzyl group from **H**. All reproduction steps happened in different generations. Positive and negative numbers are observed unfavorable and favorable score changes.

3.5 Runtime analysis

All runs were conducted on Leipzig University's high parallel computing cluster equipped with AMD EPYC 7713 @ 2.0GHz - Turbo 3.7GHz processors. We tested REvoLd runs with 20, 40, 60 and 100 cores per run. Only the first core, acting as control and distribution core, loaded the entire Enamine REAL space database using around 23GB of memory for the current library size. Most of the memory is taken by representing each fragment with a RDKit molecule object. All other cores were used

for docking alone and required less than 4GB, mainly depending on the size of the protein structure. The highly parallel code of REvoLd and its efficient development in C++ caused very fast computation times. A single run with standard settings needs between 24 and 48 hours to finish, depending on the number of used CPUs.

As visualized in Figure 6, more than 99% of the time was spent on docking molecules as REvoLd causes close to no overhead, enabling it to use fully flexible protein and ligand models. Within the time spent on computations outside of docking, most of it is caused by loading and preparing the database. The speedups gained through the usage of more CPUs are acceptable. 20 to 40 cores yield a speedup of 1.679 (optimal 2.0), 40 to 60 cores yield 1.479 (optimal 1.5). The poor speedup from 60 to 100 (1.152, optimal 1.666) is due to the implementation. The docking of a single molecule can only be executed on a single CPU and if all molecules for one generation are distributed, a CPU is idle until the next generation should be docked. Therefore, CPU numbers should be integer fractions of the number of new individuals in each generation. Since this is subject to randomness, higher CPU number have higher chances of being idle and therefore reduced speedups.




Fig. 6 The average runtime of REvoLd on different numbers of CPU cores on the high-performance compute cluster. Over 99% of all computational time is spent on docking. More than half of the remaining time is spent loading and preparing the Enamine REAL space data. The evolutionary optimization and setup of Rosetta is extremely fast and therefore neglectable.

3.6 Impact of database sizes

We ran REvoLd on different sizes of chemical spaces during its development process. From one million for the hyperparameter optimization, to around 300 million, 1.3 billion, and finally 20.1 billion, following the growth of the Enamine REAL space. The size of the chemical space had severe impact on our code development and required several restructurings. The biggest consequence of larger chemical spaces are library initialization times and memory requirements. They grew from a few seconds and several hundred megabytes to six minutes and 23GB, respectively. However, we found no sign that REvoLd’s capability to unveil low scoring compounds is affected by the database size. We found it helpful to increase the exploration parts of the protocol slightly, but

the number of individuals and generations remained constant. That means the number of required docking runs stays constant, even if the library size increases dramatically. It should be noted though that REvoLd was optimized for efficient runtimes whilst neglecting database preparation times and memory requirements. With the continued growth of combinatorial spaces, this would need reconsideration to adapt for larger quantities of reagents.

4 Discussion

With the increased availability of three-dimensional protein structures and easily accessible chemical spaces expanding into billions of molecules, structure-based drug discovery and ultra-large library screening is becoming more and more important [22, 27, 45, 54]. It is therefore crucial to improve the available protein-ligand-docking technologies to handle compound libraries of these sizes. Besides reducing the required computational time for available tools, it is also beneficial to reduce the number of required dockings. We have shown that REvoLd is a promising tool to help in that regard. Its evolutionary optimization has proven to be reliable and efficient. We were able to create highly enriched datasets for five different protein targets with only a minimal overhead of computational time. We were additionally able to observe optimization behavior comparable to medicinal chemistry practices.

REvoLd is one of several approaches which try to solve the problem of size of chemical spaces with an efficient sampling algorithm, like V-SYNTHES and Galileo [37, 44]. V-SYNTHES uses a greedy heuristic, Galileo is another evolutionary algorithm. While neither greedy nor evolutionary are inherently better than the other, the implementations of all algorithms show different performances. Galileo is more a proof of concept and is not combined with a docking protocol but accepts any score as fitness and relies on external protocols. Additionally, the authors reported that they were not able to generate good results for all their targets. REvoLd on the other hand showed convergence in all test cases. V-SYNTHES is available as a ready-to-use software and reported good results on all benchmarks, just as REvoLd. However, REvoLd shows greater enrichment (between 869 and 1,622 for REvoLd and 250 to 460 for V-SYNTHES respectively) and requires overall fewer docking runs to achieve these results (between 49,000 and 76,000 for REvoLd and 500,000 to 1,000,000 for V-SYNTHES). It should also be mentioned that V-SYNTHES requires additional docking of intermediate libraries and single fragments, causing a computational overhead of 20-35%. Additionally, we observed that REvoLd did not require more docking runs for larger combinatorial databases, whereas V-SYNTHES reported a linear complexity relation with the number of used fragments. This relationship exists within REvoLd as well, but only for memory requirements and preprocessing. It should be noted though that V-SYNTHES reported success in follow-up *in-vitro* experiments, while REvoLd is so far only benchmarked *in-silico*.

Alternative methods like Deep Docking and Chemical Space Docking propose a mixture of structure-based docking protocols and QSAR machine learning instead of sampling-based optimization [4, 18, 19]. They dock subsets of the whole chemical space, generate molecular fingerprints for all molecules and train a QSAR model on

the *in-silico* docking scores. This gives them an advantage over methods like REvoLd, because they consider information for all molecules and are therefore better suited to discover globally best hit candidates. But this is also a huge disadvantage, because they still require analyzing every molecule, which continues to become more expensive as chemical space grows. Additionally, both methods still require several million docking runs and therefore, fall short to REvoLd and V-SYNTHES. A similar number of docking runs is required for Targeted Exploration, which uses prior knowledge about binding fragments to guide the molecule selection [40]. However, the dependence on prior knowledge is also a big limitation. Together with the required number of dockings Targeted Exploration becomes less optimal as a universal solution for structure-based drug design in ultra-large chemical space.

REvoLd is well positioned among these methods and provides with its sampling capabilities a promising solution for the problem of ultra-large library screens in general. With that, two main topics require further analysis. The biggest barrier for REvoLd right now is the runtime of the employed docking protocol. Reducing the time spent docking will increase REvoLd’s speed tremendously as over 99% of the runtime is used for docking. New docking tools like DiffDock, EquiBind and DeepDock are promising candidates to lift these restrictions [10, 39, 49]. The other important topic is the reliability of our deployed scoring function when transferring REvoLd’s *in-silico* results to *in-vitro* testing. Future experiments will need to investigate how prone REvoLd is to overfitting the fitness function. This can happen if a scoring function overestimates certain interactions or substructures in a molecule compared to actual *in-vitro* findings. Overfitting becomes more important with increasing library size [35].

5 Conclusion

REvoLd is a promising novel algorithm tackling the problem of searching for potential ligands in combinatorial libraries spanning billions of compounds. Through advanced evolutionary optimization, it enables expansive docking methods for such a task. Our benchmarks have shown promising results and REvoLd reliably outperformed a random sampler over five different targets. Unlike its competing algorithms, REvoLd is capable of discovering molecules with high predicted affinity with the same number of protein-ligand dockings even in increasingly larger libraries. To date, it is the only complete pipeline to generate *in-silico* enriched, target-specific compound lists out of combinatorial chemical libraries without the need to dock several hundreds of thousands of molecules or even more. The availability of compounds through industrial make-on-demand services allows easy experimental validation of suggested hits and completely negates the need for synthetic accessibility scores. Future research will need to focus on improving the currently applied docking protocol. Speeding up the docking calculations will have a significant impact on REvoLd’s runtime performance. Additionally, while we found that *lid_root2* can be used to distinguish actives from random samples, further experiments need to investigate the predictive power of RosettaLigand and our normalization approach.

Supplementary information. Not applicable.

Acknowledgements. Computations for this work were done (in part) using resources of the Leipzig University Computing Center and of the Vanderbilt University Advanced Computing Cluster for Research and Education (ACCRE). The authors would like to thank Iaroslava Kos and Enamine LTD for their support and access to their dataset.

Declarations

5.1 Funding

The authors acknowledge the financial support by the Federal Ministry of Education and Research of Germany and by Sächsische Staatsministerium für Wissenschaft, Kultur und Tourismus in the program Center of Excellence for AI-research *Center for Scalable Data Analytics and Artificial Intelligence Dresden/Leipzig*, project identification number: ScaDS.AI. P.E.'s position is funded through an award by ScaDS.AI. J.M. is supported by an Alexander-von-Humboldt professorship. This work was further funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) through SPP2363 (460865652) and through SFB1423 (421152132). P.E. and F.L. received a fellowship from the Max Kade foundation to support their work in the Meiler laboratory at Vanderbilt University. Work in the Vanderbilt Meiler laboratory is supported through the NIH (R01 DA046138, R01 HL122010, R01 GM080403).

5.2 Competing interests

Not applicable.

5.3 Ethics approval and consent to participate

Not applicable.

5.4 Consent for publication

Not applicable.

5.5 Data availability

Protein structures are available through the protein databank (PDB) and their codes are mentioned in the paper. Known actives are available either through the PubChem repositories associated with [6] or the directory of useful decoys (DUD-E) [38]. Access to the Enamine REAL space can be requested through Enamine Ltd.

5.6 Materials availability

Not applicable.

5.7 Code availability

All code used will be available as part of the Rosetta repository <https://github.com/RosettaCommons/rosetta>.

5.8 Author contribution

Conceptualization: Paul Eisenhuth, Jens Meiler. Data curation: Paul Eisenhuth. Formal analysis: Paul Eisenhuth. Funding acquisition: Jens Meiler. Investigation: Paul Eisenhuth. Methodology: Paul Eisenhuth. Resources: Rocco Moretti, Jens Meiler. Supervision: Rocco Moretti, Jens Meiler. Software: Paul Eisenhuth. Validation: Fabian Liessmann, Paul Eisenhuth. Visualization: Paul Eisenhuth. Writing – original draft: Paul Eisenhuth. Writing – review and editing: Paul Eisenhuth, Fabian Liessmann, Rocco Moretti, Jens Meiler.

Appendix A Comparison of different normalization methods

We tested our normalization method (section 3.1) with four different n , where the penalty for high numbers of heavy atoms decreases with increasing n . To do so, we docked known actives for four of the five targets mentioned in section 3.3 against their respective proteins. These docking scores were then normalized and plotted against the number of heavy atoms (Figure A1). The results confirm the negative correlation between unnormalized scores and the number of heavy atoms as well as our expected impact of n . Whilst $n = 3$ and $n = 4$ seem to be more successful in negating the correlation, we opted to use $n = 2$. Higher n can sometimes reintroduce the negative correlation, for example for the orexin receptor. Additionally, we found a slight positive correlation desirable to actively limit the size of ligands during evolutionary optimization. However, $n = 1$ is too strict and favors fragment-like molecules. Figure A2 shows the lowest scoring molecules from the known actives for their respective targets and each normalization method. This reaffirms our findings that $n = 3$ and $n = 4$ are very similar to unnormalized scores and that $n = 1$ can result in fragment-like molecules.

Appendix B Hyperparameter optimization

Table B1 shows all settings we tested for the hyperparameter optimization on the artificial benchmark explained in section 3.2. Every setting was tested with 20 independent runs and the average enrichment is reported if not stated otherwise. Tournament selector was used for all protocols as main selector, but with varying tournament sizes. A larger tournament size means a smaller chance for less optimal molecules to remain in the population. Initially, we tested the impacts of number of generations, the size of population passing between generations and the initial population size of random molecules. The reported enrichment factor is over the empirically known hit rate of the artificial test set, which is $0.001 \frac{\text{hits}}{\text{molecule}}$, since we selected the best 1,000 molecules from the one million set as hits. Whilst this list is far from covering all possible combinations, we could observe a strong increase in enrichment and found a set of well performing and reliable parameters.

The mentioned vanilla protocol was our initial protocol focusing on optimization. No individuals were ever removed from the reproduction candidate pool which allowed already good scoring molecules to reproduce several times. The protocol passed the 15 best molecules of each generation unchanged into the next generation, produced 30




Fig. A1 Quantitative comparison of all four investigated normalization method across four targets with unnormalized scores. The same known actives as in section 3.3 were docked and their interface scores in Rosetta energy units plotted against the number of heavy atoms. The normalization methods are mentioned in section 3.1. Results of different targets are plotted all together as grey crosses, but their linear regressions are plotted individually. The unnormalized scores clearly shows the expected negative correlation between score and number of heavy atoms. Normalization with $n = 1$ on the other hand has a strong positive correlation. This correlation becomes less with increasing n until $n = 4$ starts to show a negative correlation again.

new molecules through small mutations with a bias towards changes in reagents instead of reactions and 30 more molecules through crossover. We made two slight changes to it by decreasing the reproduction numbers (Vanilla low rep) and increasing them (Vanilla high rep). Next, we came up with the protocol mentioned in section 2.6, but with only 30 molecules from each crossover instead of 60. This is named Exploration in table B1. Finally, we increased the amount of crossover to 60 which is labeled as




Fig. A2 Qualitative comparison of all four investigated normalization method across four targets with unnormalized scores. The same known actives as in section 3.3 were docked and the lowest (and therefore best) scoring compounds are shown for each target and normalization method. The normalization methods are mentioned in section 3.1. The best molecules increase in size with less strong normalization for all tested targets. $n = 4$ reports the same molecule as the unnormalized scoring. This is also true for $n = 3$ except for OX1. Additionally, ABL1 still has the same best molecule for $n = 3$.

Explore-Crossover. Although the same protocol has higher hit rates if run for more generations, we found that this would tremendously increase the runtime. Therefore, we opted for the settings highlighted in bold.

Appendix C Score distribution of co-crystallized ligand, known actives, random samples and REvoLd

We compared the results from docking known actives, the co-crystallized ligands, and the random samples as mentioned in section 3.3. Figure C3 shows that in all cases the average of the actives has a lower energy score than the random compounds, which indicates that optimizing over *lid_root2* is a valid method of finding actives. In all but one case (M1) the crystallized ligand is within the bulk of the active compounds, making it a decent proxy for the reference level of an active compound. However, the score is not a perfect classifier since there is still a large overlap between the random sample and known binders. This can be due to actual unknown binders being included in the random sample or artifacts from the in-silico docking. Nonetheless, it shows that

Table B1 Different hyperparameters tested in the artificial benchmark

Enrichment	Generations	Population Size	Initial Size	Tournament	Protocol
16.14	30	50	100	5	Vanilla
15.05	15	50	100	5	Vanilla
17.01	50	50	100	5	Vanilla
16.03	75	50	100	5	Vanilla
17.35	100	50	100	5	Vanilla
15.71	30	50	50	5	Vanilla
18.52	30	50	150	5	Vanilla
16.83	30	50	200	5	Vanilla
13.65	30	20	100	5	Vanilla
16.77	30	30	100	5	Vanilla
17.85	30	40	100	5	Vanilla
15.58	30	60	100	5	Vanilla
13.70	15	30	50	5	Vanilla
9.64	15	30	50	5	Vanilla low rep
13.29	10	50	100	5	Vanilla high rep
17.56	30	50	100	5	Exploration
18.43	30	50	200	5	Exploration
26.03	30	50	200	10	Exploration
27.43	30	50	200	15	Exploration
30.41	30	50	200	15	Explore-Crossover
24.81	15	50	200	15	Explore-Crossover
34.39	50	50	200	15	Explore-Crossover
37.29 ¹	100	50	200	15	Explore-Crossover
38.61 ²	150	50	200	15	Explore-Crossover
28.45 ²	400	50	200	15	Explore-Crossover

The reported enrichment is averaged over 20 runs if not stated otherwise. The bold line are the settings we used for our final protocol.

¹Only five runs were conducted

²Only a single run was conducted

RosettaLigand and the *lid.root2* normalization assign more negative scores to known binders and therefore enrich binding in sets of molecules.




Fig. C3 Score distribution for all five targets used in section 3.3 for their known actives, all REvoLd results, the random sample and the ligand co-crystallized with the used protein structure. The violin plots show the density for given scores. The blue horizontal lines are from top to bottom the highest reported score, the first quantile, the second quantile (or median), the third quantile and lowest reported score. The bulk of the known actives report more negative scores than the random sample, indicating that *lid.root2* can be used to enrich for activity. This is further supported by the co-crystallized score which is in all but one case within the known actives and below most of the random sample. REvoLd reports a much more negative score distribution, highlighting its optimization capabilities.

References

- [1] Acharya A, Agarwal R, Baker MB, et al (2020) Supercomputer-based ensemble docking drug discovery pipeline with application to covid-19. *Journal of Chemical Information and Modeling* 60:5832–5852. https://doi.org/10.1021/ACS.JCIM.0C01010/ASSET/IMAGES/LARGE/CI0C01010_0009.JPEG, URL <https://pubs.acs.org/doi/full/10.1021/acs.jcim.0c01010>
- [2] Bajusz D, Rácz A, Héberger K (2015) Why is tanimoto index an appropriate choice for fingerprint-based similarity calculations? *Journal of Cheminformatics* 7:1–13. <https://doi.org/10.1186/s13321-015-0069-3>, URL <http://dx.doi.org/10.1186/s13321-015-0069-3>
- [3] Bellmann L, Penner P, Gastreich M, et al (2022) Comparison of combinatorial fragment spaces and its application to ultralarge make-on-demand compound catalogs. *Journal of chemical information and modeling* p acs.jcim.1c01378. <https://doi.org/10.1021/ACS.JCIM.1C01378>, URL <https://pubmed.ncbi.nlm.nih.gov/35050621/>
- [4] Beroza P, Crawford JJ, Ganichkin O, et al (2022) Chemical space docking enables large-scale structure-based virtual screening to discover rock1 kinase inhibitors. *Nature Communications* 13:1–10. <https://doi.org/10.1038/s41467-022-33981-8>
- [5] Bohacek RS, McMartin C, Guida WC (1996) The art and practice of structure-based drug design: A molecular modeling perspective. *Medicinal Research Reviews* 16:3–50. URL [https://doi.org/10.1002/\(SICI\)1098-1128\(199601\)16:1%3C3::AID-MED1%3E3.0.CO;2-6](https://doi.org/10.1002/(SICI)1098-1128(199601)16:1%3C3::AID-MED1%3E3.0.CO;2-6)
- [6] Butkiewicz M, Lowe EW, Mueller R, et al (2013) Benchmarking ligand-based virtual high-throughput screening with the pubchem database. *Molecules* 2013, Vol 18, Pages 735-756 18:735–756. <https://doi.org/10.3390/MOLECULES18010735>, URL <https://www.mdpi.com/1420-3049/18/1/735/htmhttps://www.mdpi.com/1420-3049/18/1/735>
- [7] Chien EY, Liu W, Zhao Q, et al (2010) Structure of the human dopamine d3 receptor in complex with a d2/d3 selective antagonist. *Science* 330:1091–1095. https://doi.org/10.1126/SCIENCE.1197410/SUPPL_FILE/CHIEN.SOM.PDF, URL <https://www.science.org/doi/10.1126/science.1197410>
- [8] Chu Y, He X (2019) Molegear: a java-based platform for evolutionary de novo molecular design. *Molecules* 24(7):1444
- [9] Coley CW (2021) Defining and exploring chemical spaces. *Trends in Chemistry* 3:133–145. <https://doi.org/10.1016/J.TRECHM.2020.11.004>
- [10] Corso G, Stärk H, Jing B, et al (2023) Diffdock: Diffusion steps, twists, and turns for molecular docking. In: *International Conference on Learning Representations*

(ICLR)

- [11] Cowan-Jacob SW, Fendrich G, Floersheimer A, et al (2006) Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. *Acta Crystallographica Section D: Biological Crystallography* 63:80–93. <https://doi.org/10.1107/S0907444906047287/BA5102SUP1.PDF>, URL <http://scripts.iucr.org/cgi-bin/paper?ba5102>
- [12] DeLuca S, Khar K, Meiler J (2015) Fully flexible docking of medium sized ligand libraries with rosettaligand. *PLoS ONE* 10:1–19. <https://doi.org/10.1371/journal.pone.0132508>
- [13] Devi RV, Sathya SS, Coumar MS (2015) Evolutionary algorithms for de novo drug design – a survey. *Applied Soft Computing* 27:543–552. <https://doi.org/10.1016/j.asoc.2014.09.042>
- [14] Enamine (2024) Real space. URL <https://enamine.net/compound-collections/real-compounds/real-space-navigator>
- [15] Ertl P (2003) Cheminformatics analysis of organic substituents: Identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups. *Journal of Chemical Information and Computer Sciences* 43:374–380. <https://doi.org/10.1021/CI0255782/ASSET/IMAGES/LARGE/CI0255782F00010.JPEG>, URL <https://pubs.acs.org/doi/full/10.1021/ci0255782>
- [16] Ertl P, Schuffenhauer A (2009) Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. *Journal of Cheminformatics* 1:1–11. <https://doi.org/10.1186/1758-2946-1-8>
- [17] Gao W, Fu T, Sun J, et al (2022) Sample efficiency matters: a benchmark for practical molecular optimization. *Advances in neural information processing systems* 35:21342–21357
- [18] Gentile F, Agrawal V, Hsing M, et al (2020) Deep docking: A deep learning platform for augmentation of structure based drug discovery. *ACS Central Science* 6:939–949. https://doi.org/10.1021/ACSCENTSCI.0C00229/SUPPL_FILE/OC0C00229_SI.002.XLSX, URL <https://pubs.acs.org/doi/abs/10.1021/acscentsci.0c00229>
- [19] Gentile F, Yaacoub JC, Gleave J, et al (2022) Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking. *Nature Protocols* 2022 pp 1–26. <https://doi.org/10.1038/s41596-021-00659-2>, URL <https://www.nature.com/articles/s41596-021-00659-2>

- [20] Goldberg DE, Deb K (1991) A comparative analysis of selection schemes used in genetic algorithms. In: RAWLINS GJ (ed) Foundations of Genetic Algorithms, Foundations of Genetic Algorithms, vol 1. Elsevier, p 69–93, <https://doi.org/https://doi.org/10.1016/B978-0-08-050684-5.50008-2>, URL <https://www.sciencedirect.com/science/article/pii/B9780080506845500082>
- [21] Gorgulla C, Boeszoermyeni A, Wang ZF, et al (2020) An open-source drug discovery platform enables ultra-large virtual screens. *Nature* 2020 580:7805 580:663–668. <https://doi.org/10.1038/s41586-020-2117-z>, URL <https://www.nature.com/articles/s41586-020-2117-z>
- [22] Grygorenko OO, Radchenko DS, Dziuba I, et al (2020) Generating multibillion chemical space of readily accessible screening compounds. *iScience* 23:101681. <https://doi.org/10.1016/J.ISCI.2020.101681>
- [23] Hiss JA, Reutlinger M, Koch CP, et al (2014) Combinatorial chemistry by ant colony optimization. *Future Medicinal Chemistry* 6:267–280. <https://doi.org/10.4155/FMC.13.203>
- [24] Hopkins AL, Keserü GM, Leeson PD, et al (2014) The role of ligand efficiency metrics in drug discovery. *Nature Reviews Drug Discovery* 2014 13:2 13:105–121. <https://doi.org/10.1038/nrd4163>, URL <https://www.nature.com/articles/nrd4163>
- [25] Illgen K, Enderle T, Broger C, et al (2000) Simulated molecular evolution in a full combinatorial library. *Chemistry and Biology* 7:433–441. [https://doi.org/10.1016/S1074-5521\(00\)00122-8](https://doi.org/10.1016/S1074-5521(00)00122-8)
- [26] Irwin JJ, Shoichet BK (2016) Docking screens for novel ligands conferring new biology. *Journal of Medicinal Chemistry* 59:4103–4120. <https://doi.org/10.1021/ACS.JMEDCHEM.5B02008>/ASSET/IMAGES/LARGE/JM-2015-020088_0002.JPEG, URL <https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b02008>
- [27] Jumper J, Evans R, Pritzel A, et al (2021) Highly accurate protein structure prediction with alphafold. *Nature* pp 1–11. <https://doi.org/10.1038/s41586-021-03819-2>, URL <https://www.nature.com/articles/s41586-021-03819-2><http://www.ncbi.nlm.nih.gov/pubmed/34265844>
- [28] Kerstjens A, Winter HD (2022) Leadd: Lamarckian evolutionary algorithm for de novo drug design. *Journal of Cheminformatics* 14:1–20. <https://doi.org/10.1186/S13321-022-00582-Y>/FIGURES/17, URL <https://jcheminf.biomedcentral.com/articles/10.1186/s13321-022-00582-yhttp://creativecommons.org/publicdomain/zero/1.0/>
- [29] Landrum G, Tosco P, Kelley B, et al (2024) rdkit/rdkit: 2024.03.1 (q1 2024) release. <https://doi.org/10.5281/zenodo.10893044>, URL <https://doi.org/10.5281/zenodo.10893044>

- [30] Le TC, Winkler DA (2015) A bright future for evolutionary methods in drug design. *ChemMedChem* 10:1296–1300. <https://doi.org/10.1002/CMDC.201500161>, URL <https://onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201500161><https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201500161>
- [31] Leguy J, Cauchy T, Glavatskikh M, et al (2020) Evomol: a flexible and interpretable evolutionary algorithm for unbiased de novo molecular generation. *Journal of Cheminformatics* 12:1–19. <https://doi.org/10.1186/S13321-020-00458-Z>, URL <https://jcheminf.biomedcentral.com/articles/10.1186/s13321-020-00458-z>
- [32] Lountos GT, Zhao XZ, Kiselev E, et al (2019) Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-dna phosphodiesterase i (tdp1) phosphoryl recognition by crystallographic fragment cocktail screening. *Nucleic Acids Research* 47:10134–10150. <https://doi.org/10.1093/NAR/GKZ515>, URL <https://academic.oup.com/nar/article/47/19/10134/5519170>
- [33] Luttens A, de Vaca IC, Sparring L, et al (2023) Rapid traversal of ultralarge chemical space using machine learning guided docking screens, <https://doi.org/10.26434/CHEMRXIV-2023-W3X36>, URL <https://chemrxiv.org/engage/chemrxiv/article-details/6456778807c3f02937503688>, unpublished
- [34] Lyu J, Wang S, Balius TE, et al (2019) Ultra-large library docking for discovering new chemotypes. *Nature* 566:224–229. <https://doi.org/10.1038/s41586-019-0917-9>, URL <http://dx.doi.org/10.1038/s41586-019-0917-9>
- [35] Lyu J, Irwin JJ, Shoichet BK (2023) Modeling the expansion of virtual screening libraries. *Nature Chemical Biology* <https://doi.org/10.1038/s41589-022-01234-w>
- [36] Meiler J, Baker D (2006) RosettaLigand: Protein-small molecule docking with full side-chain flexibility. *Proteins: Structure, Function and Genetics* 65:538–548. <https://doi.org/10.1002/prot.21086>
- [37] Meyenburg C, Dolfus U, Briem H, et al (2022) Galileo: Three-dimensional searching in large combinatorial fragment spaces on the example of pharmacophores. *Journal of Computer-Aided Molecular Design* <https://doi.org/10.1007/s10822-022-00485-y>, URL <https://doi.org/10.1007/s10822-022-00485-y>
- [38] Mysinger MM, Carchia M, Irwin JJ, et al (2012) Directory of useful decoys, enhanced (dud-e): Better ligands and decoys for better benchmarking. *Journal of Medicinal Chemistry* 55:6582–6594. https://doi.org/10.1021/JM300687E/SUPPL_FILE/JM300687E_SI.004.TXT, URL <https://pubs.acs.org/doi/full/10.1021/jm300687e>

- [39] Méndez-Lucio O, Ahmad M, del Rio-Chanona EA, et al (2021) A geometric deep learning approach to predict binding conformations of bioactive molecules. *Nature Machine Intelligence* 3:1033–1039. <https://doi.org/10.1038/s42256-021-00409-9>
- [40] Müller J, Klein R, Tarkhanova O, et al (2022) Magnet for the needle in haystack: "crystal structure first" fragment hits unlock active chemical matter using targeted exploration of vast chemical spaces. *Journal of Medicinal Chemistry* <https://doi.org/10.1021/acs.jmedchem.2c00813>
- [41] OTAVA (2024) 12 billion novel molecules: Chemriya - otava's on-demand chemical space. URL <https://www.otavachemicals.com/products/chemriya>
- [42] Powers AS, Yu HH, Suriana P, et al (2023) Geometric deep learning for structure-based ligand design. *ACS Central Science* <https://doi.org/10.1021/ACSCENTSCI.3C00572>, URL <https://pubs.acs.org/doi/full/10.1021/acscentsci.3c00572>
- [43] Rogers D, Hahn M (2010) Extended-connectivity fingerprints. *Journal of Chemical Information and Modeling* 50:742–754. <https://doi.org/10.1021/ci100050t>, URL <https://pubs.acs.org/doi/10.1021/ci100050t>
- [44] Sadybekov AA, Sadybekov AV, Liu Y, et al (2022) Synthon-based ligand discovery in virtual libraries of over 11 billion compounds. *Nature* 601:452–459. <https://doi.org/10.1038/s41586-021-04220-9>, URL <https://www.nature.com/articles/s41586-021-04220-9>
- [45] Sala D, Batebi H, Ledwitch K, et al (2023) Targeting in silico gpcr conformations with ultra-large library screening for hit discovery. *Trends in Pharmacological Sciences* 44:150–161. <https://doi.org/10.1016/J.TIPS.2022.12.006>
- [46] Sliwoski G, Kothiwale S, Meiler J, et al (2014) Computational methods in drug discovery. <https://doi.org/10.1124/pr.112.007336>
- [47] Spiegel JO, Durrant JD (2020) Autogrow4: An open-source genetic algorithm for de novo drug design and lead optimization. *Journal of Cheminformatics* 12:1–16. <https://doi.org/10.1186/s13321-020-00429-4>, URL <https://doi.org/10.1186/s13321-020-00429-4>
- [48] Steinmann C, Jensen JH (2021) Using a genetic algorithm to find molecules with good docking scores. *PeerJ Physical Chemistry* 3:e18. <https://doi.org/10.7717/peerj-pchem.18>
- [49] Stärk H, Ganea OE, Pattanaik L, et al (2022) Equibind: Geometric deep learning for drug binding structure prediction. *arXiv Quantitative Biology* <https://doi.org/10.48550/arxiv.2202.05146>, URL <https://arxiv.org/abs/2202.05146v1>

- [50] Thal DM, Sun B, Feng D, et al (2016) Crystal structures of the m1 and m4 muscarinic acetylcholine receptors. *Nature* 2016 531:7594 531:335–340. <https://doi.org/10.1038/nature17188>, URL <https://www.nature.com/articles/nature17188>
- [51] Tripp A, Hernández-Lobato JM (2023) Genetic algorithms are strong baselines for molecule generation, URL <https://arxiv.org/abs/2310.09267v1>, unpublished
- [52] Veale CG (2021) Into the fray! a beginner’s guide to medicinal chemistry. *ChemMedChem* 16:1199–1225. <https://doi.org/10.1002/cmdc.202000929>
- [53] Virshup AM, Contreras-García J, Wipf P, et al (2013) Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds. *Journal of the American Chemical Society* 135:7296–7303. <https://doi.org/10.1021/ja401184g>
- [54] Warr WA, Nicklaus MC, Nicolaou CA, et al (2022) Exploration of ultralarge compound collections for drug discovery. *Journal of Chemical Information and Modeling* 62:5. <https://doi.org/10.1021/ACS.JCIM.2C00224/ASSET/IMAGES/LARGE/C12C00224.0001.JPEG>, URL <https://pubs.acs.org/doi/full/10.1021/acs.jcim.2c00224>
- [55] WuXi Biology (2024) Virtual screening. URL <https://wuxibiology.com/drug-discovery-services/hit-finding-and-screening-services/virtual-screening/>
- [56] Yang Z, Han S, Keller M, et al (2018) Structural basis of ligand binding modes at the neuropeptide y y1 receptor. *Nature* 556:520–524. <https://doi.org/10.1038/s41586-018-0046-x>
- [57] Yin J, Babaoglu K, Brautigam CA, et al (2016) Structure and ligand-binding mechanism of the human ox1 and ox2 orexin receptors. *Nature Structural and Molecular Biology* 2016 23:4 23:293–299. <https://doi.org/10.1038/nsmb.3183>, URL <https://www.nature.com/articles/nsmb.3183>